RESEARCH REPORT Dave Levitan The combination of whole-brain radiation therapy and the EGFR inhibitor erlotinib showed a promising response rate and was well tolerated in a new phase II trial of patients with brain metastases from non-small-cell lung cancer.
REVIEW ARTICLE Elgene Lim, Nancy U. Lin;ONCOLOGY Vol. 26 No. 7 This review will focus on the breast cancer subtypes with the highest incidence of breast cancer brain metastases and will characterize differences in the clinical behavior of brain metastases that arise from these different subtypes.
Central nervous system (CNS) cancers are the second most frequent malignancy in childhood. In recent years, significant advances in surgery, radiotherapy, and chemotherapy have improved survival in children with these tumors. However, a significant proportion of patients with CNS tumors suffer progressive disease despite such treatment.
• Commentary (Olson) • Commentary (Asgharzadeh/Finlay)
The purpose of this paper is to provide an overview of the clinical presentation, diagnosis, and treatment of brain metastases in patients with SCLC, with a focus on current trends and developments in the treatment of this disease.
A healthy 24-year-old male presented with a history of several months of poorly localized headaches and blurred vision. MRI of the brain demonstrated a multi-lobulated mass. Based on the radiographic appearance of the mass, what is the most likely diagnosis?